CoChat

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors

Open access

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Nanoparticles can potentially stimulate tumour microenvironments to elicit antitumour immunity. Herein, we demonstrate effective immunotherapy of colorectal cancer via systemic delivery of an immunostimulatory chemotherapeutic combination in nanoscale coordination polymer (NCP) core-shell particles. Oxaliplatin and dihydroartemesinin have contrasting physicochemical properties but strong synergy in reactive oxygen species (ROS) generation and anticancer activity. The combined ROS generation is harnessed for immune activation to synergize with an anti-PD-L1 antibody for the treatment of murine colorectal cancer tumours. The favourable biodistribution and tumour uptake of NCPs and the absence of peripheral neuropathy allow for repeated dosing to afford 100% tumour eradication. The involvement of innate and adaptive immune systems elicit strong and long lasting antitumour immunity which prevents tumour formation when cured mice are challenged with cancer cells. The intrinsically biodegradable, well tolerated, and systemically available immunostimulatory NCP promises to enter clinical testing as an immunotherapy against colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09221-x

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Preparation and characterization of OxPt/DHA. a Schematic illustration showing layer-by-layer construction of the hybrid core-shell structure of OxPt/DHA. The OxPt/DHA consists of an OxPt prodrug coordinated to Zn2+ ions in the core and chol-DHA in the lipid shell. Compositions of the three NCPs investigated are also shown. b TEM image of OxPt/DHA. c Number-average diameter of OxPt/DHA characterized by DLS. d Stability test of OxPt/DHA at 37 °C in the presence of BSA (5 mg/mL). OxPt oxaliplatin, DHA dihydroartemisinin, TEM transmission electron microscopy, DLS dynamic light scattering
Fig. 1 Preparation and characterization of OxPt/DHA. a Schematic illustration showing layer-by-layer construction of the hybrid core-shell structure of OxPt/DHA. The OxPt/DHA consists of an OxPt prodrug coordinated to Zn2+ ions in the core and chol-DHA in the lipid shell. Compositions of the three NCPs investigated are also shown. b TEM image of OxPt/DHA. c Number-average diameter of OxPt/DHA characterized by DLS. d Stability test of OxPt/DHA at 37 °C in the presence of BSA (5 mg/mL). OxPt oxaliplatin, DHA dihydroartemisinin, TEM transmission electron microscopy, DLS dynamic light scatteringCC BY · PubMed Central
Fig. 2 Internalization and dissociation of NCP components in cells. a Uptake of chol-pyro-labelled NCP particles by CT26 cells at different incubation times. b The intracellular Pt in CT26 incubated with OxPt or OxPt/DHA as determined by ICP-MS. c CT26 cells incubated with fluorescent nanoparticles containing xylenol orange in the core, chol-pyro in the shell, and FITC-DOPE lipid to visualize OxPt in the core, chol-DHA in the shell, and the lipid layer of OxPt/DHA, respectively, for different times were observed under confocal laser scanning microscopy (CLSM). The experiments were done three times and data were expressed as mean ± SD in (a) and (b). The images in (c) were obtained without repetition. NCP nanoscale coordination polymer, OxPt oxaliplatin, DHA dihydroartemisinin, ICP-MS inductively coupled plasma-mass spectrometry
Fig. 2 Internalization and dissociation of NCP components in cells. a Uptake of chol-pyro-labelled NCP particles by CT26 cells at different incubation times. b The intracellular Pt in CT26 incubated with OxPt or OxPt/DHA as determined by ICP-MS. c CT26 cells incubated with fluorescent nanoparticles containing xylenol orange in the core, chol-pyro in the shell, and FITC-DOPE lipid to visualize OxPt in the core, chol-DHA in the shell, and the lipid layer of OxPt/DHA, respectively, for different times were observed under confocal laser scanning microscopy (CLSM). The experiments were done three times and data were expressed as mean ± SD in (a) and (b). The images in (c) were obtained without repetition. NCP nanoscale coordination polymer, OxPt oxaliplatin, DHA dihydroartemisinin, ICP-MS inductively coupled plasma-mass spectrometryCC BY · PubMed Central
Fig. 3 Release of DHA and OxPt from OxPt/DHA. a Proposed DHA release via GSH-mediated disulphide cleavage and proton-catalysed hydrolysis. b Proposed release of OxPt via direct reduction by ascorbate or a two-step sequence of hydrolysis to generate OxPt-bc followed by reduction to OxPt. c Total Pt release from and chol-DHA remaining in OxPt/DHA particle when incubated in water at 37 °C with or without 0.5% Triton X-100 and 5 mM ascorbate. The data were obtained without repetition. OxPt oxaliplatin, DHA dihydroartemisinin, GSH glutathione
Fig. 3 Release of DHA and OxPt from OxPt/DHA. a Proposed DHA release via GSH-mediated disulphide cleavage and proton-catalysed hydrolysis. b Proposed release of OxPt via direct reduction by ascorbate or a two-step sequence of hydrolysis to generate OxPt-bc followed by reduction to OxPt. c Total Pt release from and chol-DHA remaining in OxPt/DHA particle when incubated in water at 37 °C with or without 0.5% Triton X-100 and 5 mM ascorbate. The data were obtained without repetition. OxPt oxaliplatin, DHA dihydroartemisinin, GSH glutathioneCC BY · PubMed Central
Fig. 4 Programmed cell death in colorectal cancer cells by ROS generation. a, b ROS generation in cells treated with OxPt/DHA, as indicated by the green fluorescence of 2′,7′-dichlorofluorescein (DCF) that was oxidized from 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) by ROS. c, d Release of cytochrome c from mitochondria in cells incubated with OxPt/DHA. Mitochondria (red fluorescence) and cytochrome c (green fluorescence) were stained by MitoTracker Red CMXRos and anti-cytochrome c antibody, respectively. e, f Apoptosis induced by OxPt/DHA. After treatment, cells were stained by Alexa Fluor 488-labelled Annexin V and propidium iodide (PI) and analysed by flow cytometry. g, h Cell cycle arrest caused by OxPt/DHA. Treated cells were fixed with 70% ethanol overnight, treated with RNase A, stained by PI, and analysed by flow cytometry. Data are expressed as means ± SD, and one of three repetitions with similar results is shown here. *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s two-tailed t test. OxPt oxaliplatin, DHA dihydroartemisinin, ROS reactive oxygen species
Fig. 4 Programmed cell death in colorectal cancer cells by ROS generation. a, b ROS generation in cells treated with OxPt/DHA, as indicated by the green fluorescence of 2′,7′-dichlorofluorescein (DCF) that was oxidized from 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) by ROS. c, d Release of cytochrome c from mitochondria in cells incubated with OxPt/DHA. Mitochondria (red fluorescence) and cytochrome c (green fluorescence) were stained by MitoTracker Red CMXRos and anti-cytochrome c antibody, respectively. e, f Apoptosis induced by OxPt/DHA. After treatment, cells were stained by Alexa Fluor 488-labelled Annexin V and propidium iodide (PI) and analysed by flow cytometry. g, h Cell cycle arrest caused by OxPt/DHA. Treated cells were fixed with 70% ethanol overnight, treated with RNase A, stained by PI, and analysed by flow cytometry. Data are expressed as means ± SD, and one of three repetitions with similar results is shown here. *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s two-tailed t test. OxPt oxaliplatin, DHA dihydroartemisinin, ROS reactive oxygen speciesCC BY · PubMed Central
Fig. 5 Immunostimulatory effects in colorectal cancer cells. a, b CRT cell surface expression upon treatment with OxPt/DHA, determined by flow cytometry (a) and CLSM (b). c HMGB-1 release from tumour cells treated with OxPt/DHA, detected by ELISA. d–f Uptake of treated MC38 cells by bone-marrow-derived dendritic cells (d) and macrophages (e). f Priming of T-cell responses triggered by OxPt/DHA. MC38 tumour cells were treated with OxPt/DHA, and injected into the right footpads of C57BL/6 mice to determine the capacity of draining lymph node cells to produce IFN-γ in response to MC38 lysates. g, h In vivo anticancer vaccination of OxPt/DHA in immunocompetent C57BL/6 mice (g) and immunodeficient Rag2−/− mice (h). The antitumour response was measured by immunizing mice with OxPt/DHA-treated tumour cells in one flank and challenging mice with untreated, live tumour cells in the opposite flank 7 days later. Data are expressed as means ± SD. One of three repetitions with similar results is shown here for (a)−(e). The result was obtained without repetition for (f)−(h) (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Student’s two-tailed t test. CRT calreticulin, OxPt oxaliplatin, DHA dihydroartemisinin, CLSM confocal laser scanning microscopy
Fig. 5 Immunostimulatory effects in colorectal cancer cells. a, b CRT cell surface expression upon treatment with OxPt/DHA, determined by flow cytometry (a) and CLSM (b). c HMGB-1 release from tumour cells treated with OxPt/DHA, detected by ELISA. d–f Uptake of treated MC38 cells by bone-marrow-derived dendritic cells (d) and macrophages (e). f Priming of T-cell responses triggered by OxPt/DHA. MC38 tumour cells were treated with OxPt/DHA, and injected into the right footpads of C57BL/6 mice to determine the capacity of draining lymph node cells to produce IFN-γ in response to MC38 lysates. g, h In vivo anticancer vaccination of OxPt/DHA in immunocompetent C57BL/6 mice (g) and immunodeficient Rag2−/− mice (h). The antitumour response was measured by immunizing mice with OxPt/DHA-treated tumour cells in one flank and challenging mice with untreated, live tumour cells in the opposite flank 7 days later. Data are expressed as means ± SD. One of three repetitions with similar results is shown here for (a)−(e). The result was obtained without repetition for (f)−(h) (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Student’s two-tailed t test. CRT calreticulin, OxPt oxaliplatin, DHA dihydroartemisinin, CLSM confocal laser scanning microscopyCC BY · PubMed Central
Fig. 6 Enhanced anti-PD-L1 immunotherapy on colorectal cancers. a Experimental design for the treatment and challenge of CT26 tumour-bearing mice. Tumours were allowed to grow for 12 days before treatment to form more immunosuppressive tumours. Then, tumour-bearing mice were intraperitoneally injected with OxPt/DHA combined with α-PD-L1 every 3 days for 12 total doses. Three months after all tumours had disappeared, mice were challenged with CT26 cells, followed by rechallenge with 4T1 1 month later. b Growth curves of CT26 tumours after treatment with OxPt/DHA combined with α-PD-L1 and challenge with CT26 cells (red arrow). c Experimental design for surgery control of CT26 tumour-bearing mice. Percentage tumour-free mice (d, f) and tumour growth curve (e, g) after challenge with CT26 cells (d, e) or rechallenge with unrelated 4T1 tumour cells (f, g) in naïve mice or OxPt/DHA and α-PD-L1-treated mice. h Growth curves of MC38 tumour on C57BL/6 after treatment with OxPt/DHA (8 mg/kg OxPt) combined with α-PD-L1. i, j Therapeutic effect of OxPt/DHA plus α-PD-L1 on C57BL/6 (i) at the dose of 16 mg/kg OxPt and Rag2−/− mice (j) at the dose of 8 mg/kg OxPt. Data are each pooled from two independent experiments and expressed as means ± SD (n = 6 except for (j); n = 5 for (j)). OxPt oxaliplatin, DHA dihydroartemisinin
Fig. 6 Enhanced anti-PD-L1 immunotherapy on colorectal cancers. a Experimental design for the treatment and challenge of CT26 tumour-bearing mice. Tumours were allowed to grow for 12 days before treatment to form more immunosuppressive tumours. Then, tumour-bearing mice were intraperitoneally injected with OxPt/DHA combined with α-PD-L1 every 3 days for 12 total doses. Three months after all tumours had disappeared, mice were challenged with CT26 cells, followed by rechallenge with 4T1 1 month later. b Growth curves of CT26 tumours after treatment with OxPt/DHA combined with α-PD-L1 and challenge with CT26 cells (red arrow). c Experimental design for surgery control of CT26 tumour-bearing mice. Percentage tumour-free mice (d, f) and tumour growth curve (e, g) after challenge with CT26 cells (d, e) or rechallenge with unrelated 4T1 tumour cells (f, g) in naïve mice or OxPt/DHA and α-PD-L1-treated mice. h Growth curves of MC38 tumour on C57BL/6 after treatment with OxPt/DHA (8 mg/kg OxPt) combined with α-PD-L1. i, j Therapeutic effect of OxPt/DHA plus α-PD-L1 on C57BL/6 (i) at the dose of 16 mg/kg OxPt and Rag2−/− mice (j) at the dose of 8 mg/kg OxPt. Data are each pooled from two independent experiments and expressed as means ± SD (n = 6 except for (j); n = 5 for (j)). OxPt oxaliplatin, DHA dihydroartemisininCC BY · PubMed Central
Fig. 7 Tumour infiltration of innate immune cells. a Immunofluorescence analysis showing the infiltration of dendritic cells and macrophages 2 days after treatment. b, c The densities of CD11c+ (b) and F4/80+ (c) cells in the whole tumours 2 days after treatment, from the confocal images of immunofluorescence staining (n = 3). d, e The percentages of dendritic cells (d), total macrophages (e) and M1 macrophages (f) by flow cytometry of cell-surface staining 12 days after the first treatment. Data are each pooled from three independent experiments for (d) and (e). Data were obtained without repetition for (f). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Student’s two-tailed t test
Fig. 7 Tumour infiltration of innate immune cells. a Immunofluorescence analysis showing the infiltration of dendritic cells and macrophages 2 days after treatment. b, c The densities of CD11c+ (b) and F4/80+ (c) cells in the whole tumours 2 days after treatment, from the confocal images of immunofluorescence staining (n = 3). d, e The percentages of dendritic cells (d), total macrophages (e) and M1 macrophages (f) by flow cytometry of cell-surface staining 12 days after the first treatment. Data are each pooled from three independent experiments for (d) and (e). Data were obtained without repetition for (f). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Student’s two-tailed t testCC BY · PubMed Central
Fig. 8 OxPt/DHA promotes tumour-specific T cell response. a Immunofluorescence analysis showing the infiltration of CD8+ T cells 12 days after the first treatment. b The density of CD8+ T cells in the tumour sections, analysed from the confocal images of immunofluorescence staining (n = 3). c CD8+ T cells in tumours by flow cytometry of cell-surface staining 12 days after the first treatment. d KSPWFTTL antigen-specific IFN-γ producing T cells detected by ELISPOT assay 12 days after the first treatment. e The percentage of effector memory T cells in total CD8+ T cells in spleens after treatment with OxPt/DHA plus α-PD-L1. Data are each pooled from two independent experiments for (c)−(e). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 by Student’s two-tailed t test. OxPt oxaliplatin, DHA dihydroartemisinin, ELISPOT Enzyme-Linked ImmunoSpot
Fig. 8 OxPt/DHA promotes tumour-specific T cell response. a Immunofluorescence analysis showing the infiltration of CD8+ T cells 12 days after the first treatment. b The density of CD8+ T cells in the tumour sections, analysed from the confocal images of immunofluorescence staining (n = 3). c CD8+ T cells in tumours by flow cytometry of cell-surface staining 12 days after the first treatment. d KSPWFTTL antigen-specific IFN-γ producing T cells detected by ELISPOT assay 12 days after the first treatment. e The percentage of effector memory T cells in total CD8+ T cells in spleens after treatment with OxPt/DHA plus α-PD-L1. Data are each pooled from two independent experiments for (c)−(e). *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 by Student’s two-tailed t test. OxPt oxaliplatin, DHA dihydroartemisinin, ELISPOT Enzyme-Linked ImmunoSpotCC BY · PubMed Central
Fig. 9 Anticancer and immune mechanisms of OxPt/DHA. left, The disruption of the lipid bilayer of OxPt/DHA upon endocytosis exposes the chol-DHA and OxPt prodrugs to triggered release by hydrolysis and/or reduction. The resultant parent drugs exhibit the expected mechanisms of action of DNA adduct formation and/or ROS generation. right, Systemically delivered OxPt/DHA can accumulate in the tumours and release the drug payload, as shown on the left, for immunogenic cell death of the cancer cells. Cell-surface CRT expression and release of DAMPs, such as HMGB1, lead to phagocytosis by macrophages and/or dendritic cells, which travel to the regional lymph node to prime T cells. Macrophages can release the antigens for DC uptake and subsequent T cell activation. The tumour-specific T cells proliferate and infiltrate into the tumour, where they can exert their cytotoxic effects. The α-PD-L1 prevents the binding of tumour PD-L1 and T cell PD-1, thereby inhibiting deactivation of the T cells
Fig. 9 Anticancer and immune mechanisms of OxPt/DHA. left, The disruption of the lipid bilayer of OxPt/DHA upon endocytosis exposes the chol-DHA and OxPt prodrugs to triggered release by hydrolysis and/or reduction. The resultant parent drugs exhibit the expected mechanisms of action of DNA adduct formation and/or ROS generation. right, Systemically delivered OxPt/DHA can accumulate in the tumours and release the drug payload, as shown on the left, for immunogenic cell death of the cancer cells. Cell-surface CRT expression and release of DAMPs, such as HMGB1, lead to phagocytosis by macrophages and/or dendritic cells, which travel to the regional lymph node to prime T cells. Macrophages can release the antigens for DC uptake and subsequent T cell activation. The tumour-specific T cells proliferate and infiltrate into the tumour, where they can exert their cytotoxic effects. The α-PD-L1 prevents the binding of tumour PD-L1 and T cell PD-1, thereby inhibiting deactivation of the T cellsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

See all 260

Metadata

Authors
Duan, X., Chan, C., Han, W., Guo, N., Weichselbaum, R. R., & Lin, W.
Affiliations
University of Chicago (US)
Corresponding author
Lin, Wenbin
Venue
Nature Communications
Published
2019-04-23
Volume
10
Issue
1
Pages
1899-1899
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2941897681
Cited by
256
References
65
Citations by year
2026: 12 · 2025: 15 · 2024: 35 · 2023: 36 · 2022: 46 · 2021: 58 · 2020: 43 · 2019: 11
FWCI
16.48
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • University of Chicago (P30 CA014599, CA014599)
  • National Institutes of Health (CA014599)
  • University of Chicago Medicine
  • National Cancer Institute (CA 014599, R01CA223184, P30CA014599)
  • National Institute of General Medical Sciences (T32GM008720)
  • Comprehensive Cancer Center, University of Chicago Medical Center (P30 CA014599, NIH CCSG: P30 CA014599, CA014599)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
colorectal cancer, immunotherapy, nanomedicine, coordination polymer nanoparticles, core-shell nanoparticles, oxaliplatin, dihydroartemisinin, reactive oxygen species, PD-L1 inhibitors, immune checkpoint blockade, combination chemotherapy, systemic drug delivery, antitumor immunity, tumor microenvironment, biodegradable nanoparticles
MeSH terms
Oxaliplatin, Adenocarcinoma, Animals, Antineoplastic Agents, Drug Compounding, Humans, Immunity, Innate, Immunologic Factors, Mice, Inbred BALB C, Neoplasm Transplantation, Polymers, Colorectal Neoplasms, Survival Analysis, Rats, Sprague-Dawley, Reactive Oxygen Species, Cancer Vaccines, Artemisinins, Cell Line, Tumor, Mice, Rats, Nanoparticles, Adaptive Immunity, Antibodies, Neutralizing, Tumor Microenvironment, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. https://app.cochat.ai/papers/10.1038/s41467-019-09221-x
The paper
Duan, X., Chan, C., Han, W., Guo, N., Weichselbaum, R. R., & Lin, W. (2019). Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Nature Communications. https://doi.org/10.1038/s41467-019-09221-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.